A Comparison of Lipiodol Chemoembolization and Conservative Treatment for Unresectable Hepatocellular Carcinoma
- 11 May 1995
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 332 (19), 1256-1261
- https://doi.org/10.1056/nejm199505113321903
Abstract
Chemoembolization with Lipiodol (iodized oil) is widely used to treat patients with unresectable hepatocellular carcinoma. Severe side effects have been reported, and improved survival has not been clearly demonstrated.Keywords
This publication has 34 references indexed in Scilit:
- Phase Ii Study of Transarterial Embolization in European Patients With Hepatocellular Carcinoma: Need for Controlled TrialsHepatology, 1994
- Hepatocellular Carcinoma in CirrhoticsSeminars in Liver Disease, 1993
- Treatment of small hepatocellular carcinomasThe Lancet, 1992
- Primary treatment of hepatocellular carcinoma by arterial chemoembolizationThe American Journal of Surgery, 1992
- Evaluation of transcatheter arterial embolization with epirubicin-lipiodol emulsion for hepatocellular carcinomaCancer Chemotherapy and Pharmacology, 1992
- Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: Results of a western comparative study in 60 patientsHepatology, 1991
- Benign and malignant nodules in cirrhotic livers: distinction based on blood supply.Radiology, 1991
- Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusionCancer, 1991
- Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oilGastroenterology, 1989
- Hepatic artery injection of I-131-labeled lipiodol. Part I. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases.Radiology, 1988